The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | The significance of the VERIFY trial in PV: paving the way for hepcidin mimetics and modulators
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the significance of the Phase III VERIFY study (NCT05210790), which demonstrated the efficacy of rusfertide, a first-in-class hepcidin mimetic, in patients with polycythemia vera (PV). Dr Pemmaraju highlights that the trial’s success has paved the way for other hepcidin mimetics and modulators, such as DISC-3405 and divesiran, which are currently in clinical trials. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m very excited that the Phase III VERIFY study, which was rusfertide, the first-in-class hepcidin mimetic, was shown at all of our major meetings, including last year at the ASCO plenary session. This study was very important as it has given the basis for a very recent FDA approval. So rusfertide, the first-in-class hepcidin mimetic, was shown versus a placebo and getting regular phlebotomies as standard of care, to be superior in terms of all endpoints...
I’m very excited that the Phase III VERIFY study, which was rusfertide, the first-in-class hepcidin mimetic, was shown at all of our major meetings, including last year at the ASCO plenary session. This study was very important as it has given the basis for a very recent FDA approval. So rusfertide, the first-in-class hepcidin mimetic, was shown versus a placebo and getting regular phlebotomies as standard of care, to be superior in terms of all endpoints. And that is reduction of the need for phlebotomies for patients with PV, but also improvement in two separate symptom scores, including fatigue. So, for patients with PV, with erythrocytosis, with elevated hematocrit count, this is now a new option representing, I would say, essentially a fourth class of drugs in PV. So hydroxyurea, the old standard of care with interferons, and then also very importantly, JAK inhibitors. So this is the fourth. The other important part of this is that there are many other drugs in clinical trials now following the success. The DISC-3405, there is the divesiran compound, there is the sapablursen, all of which are in various stages of clinical trials. And so it opens up a new class of targeted drugs for patients with PV, so-called hepcidin mimetics and modulators.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
